Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats

Experimental Animals

Volumn 55, Issue 4, 2006, Pages 357-367

  Iwamoto, Jun ^a   Seki, Azusa ^b   Takeda, Tsuyoshi ^a   Sato, Yoshihiro ^c   Yamada, Harumoto ^d   Yeh, James K ^e  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hamri Co Ltd   (Japan)

^c Mitate Hospital   (Japan)

^d FUJITA HEALTH UNIVERSITY   (Japan)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Alendronate; Alfacalcidol; Osteopenia; Ovariectomy; Rat

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BONALON; ONE ALFA; OSTEOCALCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE EROSION; BONE MASS; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; CANCELLOUS BONE; CELL COUNT; CELL SURFACE; CONTROLLED STUDY; CORTICAL BONE; DIAPHYSIS; DRUG MECHANISM; FEMALE; FEMUR; METAPHYSIS; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOPENIA; OVARIECTOMY; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; RAT; RAT STRAIN; TIBIA; TRABECULAR BONE;

ALENDRONATE; ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; FEMALE; HYDROXYCHOLECALCIFEROLS; OSTEOCALCIN; OVARIECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STRESS, MECHANICAL; TIBIA;

EID: 33746992600     PISSN: 13411357     EISSN: 13411357     Source Type: Journal    
DOI: 10.1538/expanim.55.357     Document Type: Article

References (23)

1. Azuma, Y., Oue, Y., Kanatani, H., Ohta, T., Kiyoki, M., and Komoriya, K. 1998. Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. J. Pharmacol. Exp. Ther. 286: 128-135.
2. Black, D.M., Cummings, S.R., Karpf, D.B., Cauley, J.A., Thompson, D.E., Nevitt, M.C., Bauer, D.C., Genant, H.K., Haskell, W.L., Marcus, R., Ott, S.M., Torner, J.C., Quandt, S.A., Reiss, T.F., and Ensrud, K.E. 1996. Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541.
3. Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodriguez-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C., and Liberman, U.A. Alendronate Phase III Osteoporosis Treatment Study Group (2004) Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350:1189-1199.
4. 3. Endocr. Rev. 6: 491-511.
5. Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., Palermo, L., Prineas, R., Rubin, S.M., Scott, J.C., Vogt, T., Wallace, R., Yates, A.J., and LaCroix, A.Z. 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 280: 2077-2082.
6. da Paz, L.H., de Falco, V., Teng, N.C., dos Reis, L.M., Pereira, R.M., and Jorgetti, V. 2001. Effect of l7beta-estradiol or alendronate on the bone densitometry, bone histomorphometry and bone metabolism of ovariectomized rats. Braz. J. Med. Biol. Res.34: 1015-1022.
7. Erben, R.G. 1997. Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J. Histochem. Cytochem. 45: 307-313.
8. Fujita, T. 1990 Studies on osteoporosis in Japan. Metabolism 39 (Suppl 1): 39-42.
9. Giavaresi, G., Fini, M., Gnudi, S., Aldini, N.N., Rocca, M., Carpi, A., and Giardino, R. 2001. Comparison of calcitonin, alendronate and fluorophosphate effects on ovariectomized rat bone. Biomed. Pharmacother. 55: 397-403.
10. Ito, M., Nishida, A., Koga, A., Ikeda, S., Shiraishi, A., Uetani, M., Hayashi, K., and Nakamura, T. 2002. Contribution of trabecular and cortical components to the mechanical properties of bone and their regulating parameters. Bone 31: 351-358.
11. Iwamoto, J., Takeda, T., Sato, Y., and Uzawa, M. 2004. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin. Rheumatol. 23:383-389.
12. Iwamoto, J., Seki, A., Takeda, T., Sato, Y., and Yamada, H. 2005. Effects of Risedronate on Femoral Bone Mineral Density and Bone Strength in Sciatic Neurectornized Young Rats. J. Bone Miner. Metab. 23: 456-462.
13. Kodama, Y., Nakayama, K., Fuse, H., Fukumoto, S., Kawahara, H., Takahashi, H., Kurokawa, T., Sekiguchi, C., Nakamura, T., and Matsumoto, T. 1997. Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J. Bone Miner. Res. 12: 1058-1067.
14. Kushida, K., Shiraki, M., Nakamura, T., Kishimoto, H., Morii, H., Yamamoto, K., Kaneda, K., Fukunaga, M., Inoue, T., Nakashima, M., and Orimo, H. 2004. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J. Bone Miner. Metab. 22: 462-468.
15. Mosekilde, L., Thomsen, J.S., Mackey, M.S., and Phipps, R.J. 2000. Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27: 639-645.
16. 3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 54: 370-376.
17. Parfitt, A.M., Drezner, M.K., Glorieux,.FH., Kanis, J.A., Malluche, H., Meunier, P.J., Ott, S.M., and Recker, R.R. 1987. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASMBR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2: 595-610.
18. Reichel, H., Koeffler, H.P., and Norman, A.W. 1989. The role of the vitamin D endocrine system in health and disease. N. Engl. J. Med. 320: 980-991.
19. Sato, M., Bryant, H.U., Iversen, P., Helterbrand, J., Smietana, F., Bemis, K., Higgs, R., Turner, C.H., Owan, I., Takano, Y., and Burr, D.B. 1996. Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats. J. Pharmacol. Exp. Ther. 279: 298-305.
20. Seedor, J.G., Quartuccio, H.A., and Thompson, D.D. 1991. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J. Bone Miner. Res. 6: 339-346.
21. Shiraishi, A., Takeda, S., Masaki, T., Higuchi, Y., Uchiyama, Y., Kubodera, N., Sato, K., Ikeda, K., Nakamura, T., Matsumoto, T., and Ogata, E. 2000. Alfacalcidol inhibits bone resorption and stimulate formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J. Bone Miner. Res. 15: 770-779.
22. Shiraishi, A., Higashi, S., Masaki, T., Saito, M., Ito, M., Ikeda, S., and Nakamura, T. 2002. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif. Tissue Int. 71: 69-79.
23. Shiraki, M., Kushida, K., Fukunaga, M., Kishimoto, H., Taga, M., Nakamura, T., Kaneda, K., Minaguchi, H., Inoue, T., Morii, H., Tomita, A., Yamamoto, K., Nagata, Y., Nakashima, M., and Orimo, H. 1999. The Alendronate Phase III Osteoporosis Treatment Research Group. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos. Int. 10: 183-192.